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a-HelixRfaH protein functions as both transcription anti-terminator and translation enhancer in bacteria. Recent
studies have shown that the C-terminal domain (CTD) is an a-helical hairpin (two-helix bundle) in full-
length RfaH, despite the intrinsically favored b-barrel structure. Here, we carried out ls-timescale molec-
ular dynamics (MD) simulations for the wild-type (WT) RfaH, its E48S mutant and an established model
without the intrinsically disordered region (IDR1) linking the CTD and the N-terminal domain (NTD). Our
simulations showed that the WT can be well stabilized by our RSFF1 force field, while the E48S mutant
and the model without IDR1 undergo considerable structural change, which is in good agreement with
experimental observations. The IDR1 plays important roles in stabilizing the hydrophobic environment
near the crucial E48–R138 salt-bridge as well as in tethering a4 helix in CTD to a3 helix in NTD. In
the absence of the IDR1, destabilization of key interdomain contacts and unfolding of the CTD a5 helix
were observed in the simulation. In addition, the intrinsically disordered tail of the CTD (IDR2) is also
of great significance to stabilize the bound conformation of CTD. These findings provide important impli-
cations for consideration of simulations in revealing the functions of residues invisible in a crystal
structure.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
RfaH from bacteria is a transcription factor belongs to the NusG
protein family.1,2 Most NusG-like proteins contain one or more
freely linked C-terminal domain(s) (CTD) folded in b-barrel-like
structure. By contrast, the structure of the CTD in RfaH is quite
unique (Fig. 1). As the crystal structure in Figure 1B shows, it folds
as an a-helical hairpin (two-helix bundle) and bounds with the N-
terminal domain (NTD) of the protein.2–4 RfaH also has a special
biological function in activating the expression of horizontally
transferred genes,5 some of which relate to the virulence of bacte-
ria.6 As Figure 1C shows, RfaH binds to RNA polymerase (RNAP) at
the operon polarity suppressor (ops) site5,7,8 and inhibits Rho-
dependent termination via modification of RNAP and exclusion of
the Rho cofactor NusG.2,8,9 Spontaneously, the CTD of RfaH binds
with S10 of the ribosome to facilitate the translation process.10
Thus, RfaH plays a role in both transcription and translation.11
The dual roles depend on a large structural transformation of
CTD as shown in Figure 1B and C.10,12,13 Initially in the closed state,the CTD is in an a-helix hairpin (PDBID: 2OUG) bound with NTD
and masking its RNAP binding site.14 Interaction of RfaH with its
DNA target ops triggers the dissociation of CTD and turns RfaH into
open state. In this open state, when away from the NTD, the CTD
immediately refolds to a b-barrel with five b-strands (PDBID:
2LCL).10 The binding between RNAP and the NTD in the open-state
RfaH engages in transcription. The CTD-b contacts with S10 sub-
unit of ribosome and sequentially promotes translation.2
The a to b transformation of CTD origins from its intrinsic
structural preference. As Figure 1B shows, in vitro experiments
indicated that the CTD fold as a b-barrel when isolated in water.10
In full-length RfaH, the disruption of a salt-bridge between E48 in
the NTD and R138 in the CTD by E48S substitution resulted in a
1:1 equilibrium between a-helix and b-sheet conformations for
the CTD in solution.10 Therefore, the E48–R138 salt-bridge plays
an important role in stabilizing CTD-a. Also, cleavage of the
IDR1 linker by TEV protease resulted an a to b transformation
of the CTD, suggesting that the linker connecting the two
domains is crucial for the interdomain binding. Therefore, CTD-
a only exists in the closed state in which the CTD is tightly inter-
acts with the NTD. CTD-b corresponds to the open state when the
NTD dissociates from the CTD. The large conformational change
of RfaH is quite unique, leading to new paradigm of a transformer
Figure 1. The full length RfaH from E. coil. (A) Sequence with its secondary structures (blue: helix, red: sheet) in crystal (PDB ID: 2OUG, closed state) given below. (B)
Transition from the closed state (left) to the open state (right). The experimental structures of its N-terminal domain (NTD) and C-terminal domain (CTD) are shown in
different colors. The NMR structure of isolated CTD (PDB ID: 2LCL) is used for the open state. The intrinsically disordered regions (IDR1 and IDR2) are invisible in the crystal
structure. (C) Model for the dual roles of RfaH in vivo.
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lead to different functions have been found previously, including
lymphotactin17 and Mad218, but they are less dramatic than RfaH.
The above significant conformational change from CDT-a in the
closed state to CDT-b in the open state attracted several theoretical
studies. On the isolated CTD, Li et al. carried out steered MD
simulations in implicit solvent and built up an a to b transition net-
work with Markov State model analysis.12 Xiong et al. used MD
simulations of coarse-grained off-lattice model to study the folding
and allostery in the full-length RfaH. Results show that a to btransition can be approximately described by a two-state model
and three parallel pathways.19 Ramírez-Sarmiento et al. built up
a dual basin model that biased the full-length RfaH to fold from
a to b state, which stresses the requirement of disruption of
interdomain contacts to trigger the a to b transformation.20 Most
recently, Jeevan et al. investigated a to b transformation of
CTD in the full-length RfaH using targeted and steered MD to
illustrate the role of interdomain interactions,21 and found that
interdomain contacts may be the main barrier in the
transformation.
4972 S. Xun et al. / Bioorg. Med. Chem. 24 (2016) 4970–4977While the importance of CTD–NTD interdomain contacts in sta-
bilizing the closed state is well appreciated,20 the role of the linker
between the two domains in stabilizing the closed state has not
been well understood. As Figure 1 shows, the linker and the C-ter-
minal tail are invisible in X-ray crystallography.21 NMR experi-
ments in solution also indicate that these two regions have no
significant preference to certain secondary structure.8 Therefore,
they are regarded as intrinsically disordered regions (IDRs). IDRs
and intrinsically disordered proteins (IDPs) lack stable tertiary
structures under physiological conditions, but can still have a vari-
ety of biological functions.22 They are often functionally important
complementary to ordered domains,23 and have been attracting
increasing attentions recently.24,25 Long disordered segments are
abundant in eukaryotes and especially enriched in proteins
involved in gene expression regulations and signaling transduc-
tions.26 Traditional structural biology methods (X-ray and NMR)
have limitations in studying intrinsic disorder, providing an excit-
ing opportunity for MD simulations.27 However, reliably describing
the structural and dynamic features of intrinsically disordered
regions or proteins using MD simulations is challenging because
of a high demand on the accuracy of the force field.28,29
We recently developed two residue-specific force fields, RSFF1
and RSFF2, by modifying the OPLS-AA/L and AMBER99 force fields
with residue-specific dihedral-angle (/, w, v1, v2, etc.) functions
for the twenty amino acid residues.30,31 The parameters were opti-
mized by fitting the dihedral-angle free energy surfaces of the
twenty dipeptide models from MD simulations to those obtained
from the statistical analysis of residues outside secondary struc-
ture regions (coil library) in high-resolution protein PDB struc-
tures.32,33 These force fields have been successfully applied in
simulating the folding34,35 and refinement36 of proteins. Very
recently, we have successfully folded a designed a-helical hairpin
motif (ata) using both RSFF1 and RSFF2.37 We have also shown
that these force fields have advantages in studying cyclic pep-
tides.38 Here we report the application of the RSFF1 in the study
of the full-length RfaH to test whether it can stabilize the protein,
to understand the role of the E48–R138 salt-bridge, and most
importantly, the role of the intrinsically disordered linker connect-
ing CTD and NTD in stabilizing the closed state of the protein.
2. Methods
The crystal structure of RfaH in the closed state was down-
loaded from the Protein Data Bank39 (ID: 2OUG). The IDR1
(P101–D114) and IDR2 (T157–L162) regions invisible in the crystal
structure were built using structure prediction program
MODELLER40,41 embedded in Chimera 1.8,42 by providing the crys-
tal structure as the template. The E48S mutant was built using the
mutation tool in PyMOL 1.2.43
All simulations were done using the Gromacs 4.5.444,45 software
with the RSFF1 force field.31 Each protein was solvated in an octa-
hedron box (length 59.5 Å) of TIP4P–Ew water. Na+ or Cl ions at
0.05 mol/L were added to neutralize the system. The electrostatic
interactions were treated using the PME method46 with a 9 Å
real-space cutoff. The cutoff of van der Waals interactions is also
9 Å, and the energy and pressure were corrected for long-range dis-
persion interactions. The integration step time was set to 3 fs. All
bonds involving hydrogen atoms were constraint using the LINCS.
The Berendsen method was used for temperature coupling and
pressure coupling at 1 atm. After a 5000-step energy minimization,
a 5 ns NPT simulation was performed with temperature increased
from 10 K to 310 K in the first ns. During this pre-equilibrium pro-
cess, all Ca atoms were restrained by harmonic potentials at 10 kJ/
(mol Å2). The last snapshot was used as the initial structure forsubsequent productive NPT simulation at 310 K. Structures were
stored every 1.5 ps. The simulation time for each system is 2.1 ls.
The secondary structure assignments were done using DSSP.47
PyMOL 1.2 was used to draw all graphics of protein structures.43
Binding free energy decomposition was estimated with the
GBSA48,49 model using the MMPBSA.py tool from AmberTools15.50
Although this method is found to overestimate binding free
energy,51,52 it can give meaningful relative strength of binding.53
The crystal structure (2OUG) after a 5000-step energy minimiza-
tion was used for the MM/GBSA calculation. We use ‘Gromos’
method54 (cutoff = 2.5 Å) to cluster 5000 structures from 1200 ns
to 2100 ns in WT runs according to the coordinates of side chains
of IDR1 + (K115–G121) and IDR2. For E48S mutant and model
without IDR1, the coordinates of all Ca atoms were selected for
clustering analysis. Chemical shifts from simulations were calcu-
lated using SPARTA+.55
3. Results and discussion
3.1. Agreement with previous observations
Two independent MD simulations were performed on the wide-
type (WT) RfaH in parallel. The E48S mutant and a model without
the linker between the NTD and the CTD (no-IDR1) were also sim-
ulated. As shown in Figure 2, after 1000 ns of the WT simulations,
the overall Ca-RMSD to the crystal structure leveled off around
2.3 Å and 2.8 Å for run A and run B, respectively. Interestingly,
there is an initial increase of RMSD to as high as 6 Å in the WT sim-
ulation run B, but it is decreased back to <3 Å after that. Our sim-
ulations indicate that the WT can be well stabilized by the force
field. Also in agreement with previous in vitro experiments,10 the
MD simulations of E48S mutant and the no-IDR1 model give higher
Ca-RMSD values, which are about 5.0 Å to the crystal structure
near the end of the simulations. Indeed, considerable structural
changes appear in the E48S mutant simulation, with the b3-b4
hairpin moving significantly away from the CTD and the hydropho-
bic contacts around the salt-bridge broken (Fig. S1). When only
looking at the CTD, the structured sampled in the WT simulations
always have smaller RMSD, compared with the E48S and no-IDR1
simulations during 1.2–2.1 ls (Fig. 2B). However, the full a to b
conformational transition of the CTD is not observed in our simu-
lations with the time-scale of microseconds. Indeed, other small
b-barrel proteins such as SH3 can have a folding time beyond mil-
liseconds,56 so it should be very difficult to achieve the folding
without using an enhanced sampling method.
Among the interdomain contacts, the E48–R138 salt-bridge has
been considered as a key interaction to stabilize the a-helical hair-
pin structure of the CTD.10 Our MM/GBSA calculations also found
that the contributions from the salt-bridge to the total NTD–CTD
binding free energy is much stronger than those of other residue
pairs (Fig. S4). As shown in Figure 3, the salt-bridge is buried by
some hydrophobic residues in our simulations, with the solvent
accessible surface area (SASA) of R138 near zero, in good agree-
ment with those observed in the crystal structure. The hydropho-
bic core (I33, L35, F51, L50, P52, L96, F126, F130) around the
salt-bridge also form an interdomain interface between NTD and
CTD. Especially, F130 and F126 in a4 have strong contacts with
the hydrophobic residues L50 and F51 near the E48, in agreement
with previous computational studies.19,21 Indeed, a previous com-
putational study also indicated the importance of F130 and F126 in
keeping interdomain contacts.20,21
We calculated the average Ca and CO chemical shift indices
(CSI) from the structures sampled in the two WT simulations to
make a comparison with direct NMR measurements. The CSI is
Figure 2. (A) Time evolutions of overall Ca-RMSD (in Å) from two simulations of
WT RfaH (runA, runB), one simulation of the E48S mutant, and one simulation
without the IDR1 loop (no-IDR1), using the crystal structure (2OUG) as the
reference. (B) Time evolutions of Ca-RMSD (in Å) of the CTD (G121–N156) with
respect to the crystal structure. (C) The representative structure (center of the most
populated cluster) from the last 900 ns of each WT simulation, superposed on the
crystal structure. The IDR1 and IDR2 regions are omitted for clearer comparison.
S. Xun et al. / Bioorg. Med. Chem. 24 (2016) 4970–4977 4973defined as the difference between the NMR chemical shift (in ppm)
and the reference value from a random coil state. As shown in Fig-
ure 4, the calculated CSIs for secondary structure regions agree
with the experimental CSI reasonably well. In general, both exper-
iments and simulations give positive CSI (of both Ca and CO) in a-
helix region and negative CSI in b-sheet regions. In addition, our
simulations can reproduce the experimental observation of quite
negative CSI for some residues in loop regions including the
IDR1, indicating that our RSFF1 force field can describe loop confor-
mations reasonably well. There are also good correlations between
experimental and calculated raw chemical shifts (Fig. S2, Pearson
correlation R = 0.97 for Ca and R = 0.87 for CO).
Interestingly, NMR experiments give near zero CSI for the first
six residues in the helix a4 (V116-G121),10 which can be captured
in our simulations. This indicates that this secondary structure
region observed in crystal is not stable in solution. As shown in Fig-
ure 2C, the representative structures from the two WT simulations
are very similar to the crystal structure, except for a noticeable dif-
ference in the N-terminal part of the a4. During the simulation,
residues V116-G121 in a4 gradually lose their helicity (Fig. S3). Itis known that Gly residue is an a-helix breaker, and the four b-
branched residues (V116, I117, I118, T119) in this segment also
do not favor a-helix conformation.57,58 Thus, this N-terminal part
of a4 can be regarded as a part of the intrinsically disordered lin-
ker. Nevertheless, the definition of secondary structures from the
crystal structure, as shown in Figure 1A, is used throughout the
paper for consistency. Also interestingly, both the V116 and
G121 residues are fully conserved among RfaH proteins from dif-
ferent organisms, the Escherichia coli NusG, and the most distant
RfaH ortholog (TaA protein, 17% sequence identity).59
3.2. The IDRs are involved in the NTD–CTD binding
Interestingly, we found that this hydrophobic cluster around
the salt-bridge is also in contact with the disordered linker
(IDR1) between the NTD and the CTD. Figure 5 gives schematic dia-
grams illustrating interactions between IDRs and other parts,
according to the residue–residue contact maps from simulations
(Fig. S5). Although the two WT simulation runs give different rep-
resentative structures of the IDR1 linker, both simulations give
similar features in its binding mode. We found that IDR1 can tether
the CTD to the NTD through some side-chain hydrophobic interac-
tions. In WT simulation run A, P101 and I104 contact simultane-
ously with Y99/L96/Q95/V92 on a3 (NTD) and F123/F130 on a4
(CTD). In WT simulation run B, proline residues (P101, P107,
P110, P112) in IDR1 can have contacts with a3 and a4, with a dif-
ferent conformation of IDR1 observed. From both simulations,
F123 on a4 plays an important role in interacting with IDR1. This
may contribute to the fact that this residue is always kept in a-
helix conformation when those preceding it (V116–G121) are
unfolded in solution. Besides, in simulation run A we found that
K115 can form salt-bridge with D106, and hydrophobic contacts
using its aliphatic chain with some non-polar residues (P107,
P110) in IDR1. Figure 5 also gives the distance distributions of resi-
due-pairs mentioned above, from MD simulations. Most of them
have distances within 5.5 Å in most of the times, implying strong
interactions between the IDR1/IDR2 and other parts.
Besides the IDR1, the IDR2 region also interacts with other parts
of the CTD in the simulations. Especially, a residue with large side-
chain in IDR2 can insert into the space between a4 and a5. As
shown in Figure 5A, in simulation run A, R160 inserts into the area
between a4 and a5 and form salt-bridges with D114 and E149. In
simulation run B (Fig. 5B), F159 inserts its side chain between a4
and a5, and K161 forms salt-bridges with E120 and E124. These
interactions can be quite stable, with contacts formed in most of
the time except for K161-E120 (Fig. 5C and D). In general, posi-
tively charged residues on IDR2 tend to form salt-bridges with neg-
atively charged residues on other part of the CTD. Thus, IDR2 may
not only prevent a5 from unfolding, but also acts as a clamp to help
stabilize the region connecting IDR1 and a4.3.3. The CTD are destabilized without the IDR1 linker
Above results have shown that the IDR1 linking the two
domains play an important role. To further explore the conse-
quence without the IDR1, an 2.1 ls MD simulation was carried
out for the no-IDR1 model, in which the P101-D114 segment was
removed. To avoid the effects of terminal changes, the dangling
residues K100 and K115 were capped by N-methyl and Acetyl
groups, respectively. As shown in Figure 6, in the no-IDR1 simula-
tion, the E48–R138 salt-bridge is not formed (heavy-atom distance
>4 Å) for the most of the time, and the R138 is no longer fully bur-
ied (Fig. 6C). Some residues (S139, F130, F123, L96, P52, L35 and
I33) in the hydrophobic cluster around the E48–R138 salt-bridge
also have larger solvent exposure in the no-IDR1 simulation. Thus,
Figure 3. Detailed views of the region around the E48–R138 salt-bridge, from the crystal structure and the representative structures from the two WT simulations.
Figure 4. Experimental (open black bars) and calculated (green dots) chemical shift indices (CSI) of backbone Ca and CO (carbonyl carbon) atoms for WT RfaH along the
sequence. The calculated CSI are averages of values from simulations run A and run B. The secondary structures in its crystal structure are also indicated.
4974 S. Xun et al. / Bioorg. Med. Chem. 24 (2016) 4970–4977without the IDR1, the salt-bridge may be more likely to be
destroyed by the solvent.
We also observed a significant structural change of the CTD
(G121–N156). As shown in Figure 6, the CTD in the no-IDR1 simu-
lation undergoes a loss of helicity for about two turns staring fromE149 in the a5. In the WT simulations, some large side-chains on
IDR2 can insert into the space between the beginning of a4 and
the end of a5 (Fig. 5). However, this does not occur in the structure
from the no-IDR1 simulation. There is no space between a4 and a5
to allow the insertion of IDR2, and the IDR2 has less contact with
Figure 5. The key interactions involving the intrinsically disordered regions (IDRs) and the E48–R138 salt-bridge, from the WT simulations run A (A and C) and run B (B and
D). (A and B) Schematic diagrams illustrating the hydrophobic (black dashed lines) and salt-bridge (red dashed lines) interactions, with some detailed views of the
representative structures given in blue boxes. (C and D) Distributions of minimum heavy-atom distances of key residue pairs between IDRs and other parts.
S. Xun et al. / Bioorg. Med. Chem. 24 (2016) 4970–4977 4975a4 and a5. The unfolding of the last two turns of the a5 can also be
seen from residue-wise RMSD shown in Figure 7. Interestingly, this
part is away from the IDR1, which is linked to the N-terminal of the
a4. Thus, the unraveling of the a5 helix in no-IDR1 simulation can-
not be simply explained by the tail flexibility of the new ends cre-
ated by removing IDR1.
As shown in Figure 8, in the structures from no-IDR1 simula-
tion, the N-terminal part of a4 (K115-G121) significantly bends
toward the a5, which cannot occur when the IDR1 exists to hold
the position of the a4 N-terminal. With this bending, K115 can
move to form salt-bridge with E149, and E149 move to a very dif-
ferent orientation. This effect may contribute to unravel the a5 a-
helix. Besides, in WT simulation run A, R160 on IDR2 forms salt-
bridges with both D114 on IDR1 and E149 on a5. The R160–E149
salt-bridge may help to stabilize the half-buried E149 on the a5
and keep the structure of this a-helix. Without the salt-bridge
from IDR1, the IDR2 may not be stabilized in some structures
for R160 to interact with E149. Similarly, in WT simulation run
B, the F159–H152 interaction may help to stabilize the a5, and
the position of F159 may be hold by salt-bridge from K161
(Fig. 5).4. Summary
In this study, we simulated the full-length RfaH protein in the
closed state, using our recently developed RSFF1 force field. In
two parallel simulations of 2.1 ls each, the crystal structure is well
stabilized. The simulations also well reproduce the NMR chemical
shifts of the protein in solution, including those of the two intrin-
sically disordered regions invisible in the crystal: (1) IDR1 that is
the linker between NTD and CTD, (2) IDR2 at the C-terminal tail
of the CTD. In addition, both our simulations and NMR experiments
indicate that the first six residues in helix a4 observed in the crys-
tal structure are unraveled when the protein is in solution.
Further analysis indicated that among interdomain contacts the
E48–R138 salt-bridge is crucial for NTD–CTD binding, because it is
buried by hydrophobic residues from both NTD and CTD. The IDR1
can facilitate the formation of the hydrophobic cluster around this
key salt-bridge. It also directly interacts with both NTD and CTD
simultaneously, using its hydrophobic residues including several
prolines. Besides, the IDR2 can insert into the space between the
a4 and the a5 helices in CTD. These interactions may contribute
to the stabilization of the CTD in a-helical hairpin form.
Figure 6. (A) The representative structure (largest cluster center) from the last 900 ns of the no-IDR1 simulation, superimposed on the crystal structure. A detailed view of the
area around E48–R138 is also given in the middle box. (B) Distribution of minimum heavy-atom distance for the E48–R138 residue pair. (C) Average solvent accessible surface
area (SASA) of residues related to the E48–R138 salt-bridge and the surrounding interdomain hydrophobic cluster, from the simulations of WT RfaH and the model without
IDR1.
Figure 7. The RMSD for each five-residue segment after locally aligned to the
crystal structure (local RMSD) from the MD simulations of the WT, the E48S mutant
(orange) and the no-IDR1 model (grey).
Figure 8. Detailed view of the terminal part of the a-helical hairpin of CTD, from
the crystal structure and simulations with and without the IDR1 region. Some key
residues are labeled and the orientations of the K115 and E149 are shown by blue
and red arrows, respectively.
4976 S. Xun et al. / Bioorg. Med. Chem. 24 (2016) 4970–4977Compared with the simulation of the wild-type RfaH, the simu-
lations of its E48S mutant and a model without IDR1 linker give
much larger deviation from the crystal structure, in good agree-
ment with experiments. When the disordered IDR1 linker is
removed, the salt-bridge is quickly destabilized and structural
changes can occur before the dissociation of the CTD from the NTD.
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